India, Sept. 9 -- AIM ImmunoTech Inc. (AIM) highlighted the scientific rationale, supportive data and continued clinical development of Ampligen (rintatolimod) in pancreatic cancer in a new installment of its CEO Corner video series.
AIM's CEO Thomas K. Equels discussed the challenges of treating pancreatic cancer, including its highly immunosuppressive or "cold" tumor microenvironment, which can limit immune responses and reduce the effectiveness of immunotherapy approaches.
Ampligen is an investigational Toll-like receptor 3 (TLR3) agonist designed to activate innate immunity and potentially reshape the tumor microenvironment, with the goal of making tumors more responsive to checkpoint inhibitors.
The company believes Ampligen may hav...